Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
#Transmucosal Drug Delivery Devices Market Size And Revenue Outlook Through 2030#_x000D_
The transmucosal drug delivery devices market size has experienced robust growth in recent years. This market is projected to expand from $54.63 billion in 2025 to $59.61 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.1%. Historically, this growth can be attributed to several factors, including the expansion of non-invasive drug delivery approaches, a rising demand for pain management therapies, increased use of hormone replacement treatments, growth in pharmaceutical formulation innovation, and wider acceptance of transmucosal therapies._x000D_
_x000D_
The transmucosal drug delivery devices market is anticipated to show significant expansion over the coming years, with its value projected to reach $81.52 billion in 2030, growing at a compound annual growth rate (CAGR) of 8.1%. This upward trend during the forecast period can be linked to several factors, including the increasing progress in personalized medicine solutions, heightened investments in advanced drug delivery platforms, a rising need for at-home drug administration devices, the broadening application of biologics and peptide-based drugs, and an increase in regulatory approvals for innovative delivery systems. Noteworthy trends for this period encompass the growing adoption of buccal and sublingual delivery methods, an escalating demand for drug administration with rapid onset, the spread of microneedle and active delivery technologies, an enhanced focus on patient-convenient drug delivery devices, and a stronger emphasis on dose precision and bioavailability._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Transmucosal Drug Delivery Devices Market Demand Drivers Opening New Revenue Streams#_x000D_
The increasing incidence of chronic illnesses is anticipated to boost the expansion of the transmucosal drug delivery devices market in the foreseeable future. A chronic illness is defined as a persistent ailment that usually advances gradually and endures for an extended period, frequently necessitating continuous medical intervention to manage its manifestations and avert adverse effects. The rise in chronic conditions can be attributed to several factors, including lifestyle choices, an aging global demographic, environmental influences, difficulties within healthcare systems, and increasing urbanization. For chronic ailments, transmucosal drug delivery devices serve to ensure regulated and effective administration of medicines, thereby maintaining consistent therapeutic concentrations crucial for symptom control and enhancing patient compliance. As an illustration, in June 2024, data from the National Health Service, a UK-based government department, revealed that 3,615,330 individuals registered with a general practitioner (GP) had a diagnosis of non-diabetic hyperglycemia or pre-diabetes (a state characterized by elevated blood sugar levels, insufficient for a diabetes classification) in 2023. This represented an 18% increase from 3,065,825 cases reported in 2022. Consequently, the expanding occurrence of chronic diseases is fueling the transmucosal drug delivery devices market._x000D_
_x000D_
#Transmucosal Drug Delivery Devices Market Segment Analysis Spotlighting Growth Areas#_x000D_
The transmucosal drug delivery devices market covered in this report is segmented – _x000D_
_x000D_
1) By Type: Buccal Drug Delivery Devices, Sublingual Drug Delivery Devices, Nasal Drug Delivery Devices, Rectal Drug Delivery Devices, Vaginal Drug Delivery Devices_x000D_
2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types_x000D_
3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications_x000D_
4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals_x000D_
_x000D_
Subsegments:_x000D_
1) By Buccal Drug Delivery Devices: Mucoadhesive Buccal Tablets, Buccal Patches, Buccal Films_x000D_
2) By Sublingual Drug Delivery Devices: Sublingual Tablets, Sublingual Films, Sublingual Sprays_x000D_
3) By Nasal Drug Delivery Devices: Metered Dose Nasal Sprays, Nasal Powder Devices, Nasal Gel Applicators_x000D_
4) By Rectal Drug Delivery Devices: Rectal Suppositories, Rectal Gels_x000D_
5) By Vaginal Drug Delivery Devices: Vaginal Rings, Vaginal Tablets, Vaginal Gels_x000D_
_x000D_
#Transmucosal Drug Delivery Devices Market Trends Powering Strategic Industry Growth#_x000D_
Leading companies in the transmucosal drug delivery sector are developing advanced smart platforms, including proprietary transdermal patch delivery systems that boost drug absorption and enhance patient compliance and convenience. These proprietary transdermal patch delivery platforms refer to specialized, company-owned technologies for administering medications through the skin, ensuring controlled release and improved therapeutic outcomes. For instance, in January 2024, Starton Therapeutics Inc, a US-based biotechnology company, introduced STARSILON, a new proprietary transdermal patch delivery platform, designed for longer-duration therapeutic delivery of difficult-to-formulate active pharmaceutical ingredients (APIs). This expands transdermal drug delivery options for challenging APIs, enhancing therapeutic efficacy with sustained delivery rates._x000D_
_x000D_
#Transmucosal Drug Delivery Devices Market Top Companies Driving Competitive Growth#_x000D_
Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Noven Pharmaceuticals, Antares Pharma Inc., Satsuma Pharmaceuticals Inc., AdvaCare Pharma LLP, Lifevision Healthcare Private Limited, SAVA Healthcare Limited, Kaizen Pharmaceuticals Pvt. Ltd., Maya Biotech Pvt. Ltd _x000D_
_x000D_
#View The Full Transmucosal Drug Delivery Devices Market Report:#_x000D_
_x000D_
#Transmucosal Drug Delivery Devices Market Global Footprint: Which Region Leads The Industry?#_x000D_
North America was the largest region in the transmucosal drug delivery devices market in 2025. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.